<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761614</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-20096</org_study_id>
    <secondary_id>NCI-2021-00018</secondary_id>
    <nct_id>NCT04761614</nct_id>
  </id_info>
  <brief_title>Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase I Study of Riluzole in Combination With mFOLFOX6/Bevacizumab in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ning Jin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial is to find out the best dose, possible benefits, and/or side effects of&#xD;
      riluzole and how well it works in combination with standard of care mFOLFOX6 and bevacizumab&#xD;
      in treating patients with colorectal cancer that has spread to other places in the body&#xD;
      (metastatic). Riluzole is a well-tolerated oral medication that has demonstrated it may make&#xD;
      chemotherapy work better. Chemotherapy drugs, such as oxaliplatin, leucovorin calcium and&#xD;
      fluorouracil, work in different ways to stop the growth of [cancer/tumor] cells, either by&#xD;
      killing the cells, by stopping them from dividing, or by stopping them from spreading.&#xD;
      Bevacizumab is an antibody that targets the blood vessel by blocking the activity of a&#xD;
      protein called vascular endothelial growth factor alpha (VEGF-A). It helps to make the&#xD;
      mFOLFOX6 more effective. Giving riluzole, mFOLFOX6, and bevacizumab may kill more tumor cells&#xD;
      compared to mFOLFOX6 and bevacizumab alone in treating patients with colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Characterize the safety and toxicity of riluzole in combination with modified (m)&#xD;
      leucovorin calcium, fluorouracil, and oxaliplatin (FOLFOX) 6/bevacizumab and determine the&#xD;
      recommended phase II dose (RP2D) of riluzole in combination with mFOLFOX6/bevacizumab in&#xD;
      patients with metastatic colorectal cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the pharmacokinetics of riluzole in patients with metastatic CRC.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Assess the efficacy of the combination treatment. II. Determine the effect of riluzole in&#xD;
      downstream GRM3 signaling by immunofluorescent staining of phosphorylated (p)AKT and pCREB in&#xD;
      pre- and post-treatment tumor tissues.&#xD;
&#xD;
      III. Assess FCGRT/FcRn expression, bevacizumab pharmacokinetics, inflammatory cytokines, and&#xD;
      cachexia associated factors as early biomarkers for resistance to therapy.&#xD;
&#xD;
      IV. Assess cytotoxic T cells in peripheral blood to evaluate the immunomodulatory effect of&#xD;
      this therapy.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of riluzole.&#xD;
&#xD;
      Patients receive riluzole orally (PO) twice daily (BID) on days 1-14. Patients also receive&#xD;
      oxaliplatin via intravenous piggyback (IVPB) over 2 hours, leucovorin calcium IVPB over 2&#xD;
      hours, and bevacizumab IVPB over 30 minutes on day 1 and fluorouracil via intravenous (IV)&#xD;
      push over 5 minutes and then IV continuously over 46 hours on days 1-2. Treatment repeats&#xD;
      every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 4 weeks (2 cycles of treatment) (1 cycle = 14 days)</time_frame>
    <description>Will be defined by treatment related grade &gt;= 4 adverse events or &gt;= grade 3 alanine aminotransferase or aspartate aminotransferase elevation during the DLT period using the Common Terminology Criteria for Adverse Events version 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of riluzole (Cmax)</measure>
    <time_frame>Day 1 on cycle 1 (each cycle is 14 days)</time_frame>
    <description>K data analysis will utilize a nonlinear mixed effects approach whereby PK parameter estimates will be generated from the data, and 'dose day' will be evaluated as a covariate on clearance and volume of distribution. The PK parameters including Cmax. Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of riluzole (AUC)</measure>
    <time_frame>Day 1 on cycle 1 (each cycle is 14 days)</time_frame>
    <description>PK data analysis will utilize a nonlinear mixed effects approach whereby PK parameter estimates will be generated from the data, and 'dose day' will be evaluated as a covariate on clearance and volume of distribution. The PK parameters including AUC. Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Objective response rate (complete response + partial response)</measure>
    <time_frame>Up to 112 days</time_frame>
    <description>Will be estimated along with exact 95% confidence interval.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in phosphorylated (p)AKT and pCREB levels</measure>
    <time_frame>Up to 42 days (each cycle is 14 days)</time_frame>
    <description>Will be summarized using mean +/- standard error of mean, range, and median at each time point. Graphical analyses will be largely used to assess potential patterns and relationships.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in FCGRT/FcRn expression</measure>
    <time_frame>Day 1 of cycle 1, 3, 5, 7 (each cycle is 14 days)</time_frame>
    <description>Will be assessed using peripheral blood and summarized using mean +/- standard error of mean, range, and median at each time point. Graphical analyses will be largely used to assess potential patterns and relationships.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in bevacizumab clearance (Cmax)</measure>
    <time_frame>Day 1 of cycle 1, 3, 5, 7 (each cycle is 14 days)</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in bevacizumab clearance (AUC)</measure>
    <time_frame>Day 1 of cycle 1, 3, 5, 7 (each cycle is 14 days)</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </other_outcome>
  <other_outcome>
    <measure>interleukin 6</measure>
    <time_frame>Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)</time_frame>
    <description>Cytokines</description>
  </other_outcome>
  <other_outcome>
    <measure>leukemia inhibitory factor</measure>
    <time_frame>Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)</time_frame>
    <description>Cytokines</description>
  </other_outcome>
  <other_outcome>
    <measure>Necrosis factor alpha</measure>
    <time_frame>Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)</time_frame>
    <description>Cytokines</description>
  </other_outcome>
  <other_outcome>
    <measure>Interferon gamma</measure>
    <time_frame>Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)</time_frame>
    <description>Cytokines</description>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)</time_frame>
    <description>Cytokines</description>
  </other_outcome>
  <other_outcome>
    <measure>ferritin</measure>
    <time_frame>Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)</time_frame>
    <description>Cytokines</description>
  </other_outcome>
  <other_outcome>
    <measure>metalloproteinases 1</measure>
    <time_frame>Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)</time_frame>
    <description>Cytokines</description>
  </other_outcome>
  <other_outcome>
    <measure>body weight</measure>
    <time_frame>Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)</time_frame>
    <description>Will include body weight and summarized using mean +/- standard error of mean, range, and median at each time point. Graphical analyses will be largely used to assess potential patterns and relationships.</description>
  </other_outcome>
  <other_outcome>
    <measure>skeletal muscle index</measure>
    <time_frame>Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)</time_frame>
    <description>Will include skeletal muscle index and summarized using mean +/- standard error of mean, range, and median at each time point. Graphical analyses will be largely used to assess potential patterns and relationships.</description>
  </other_outcome>
  <other_outcome>
    <measure>body serum albumin</measure>
    <time_frame>Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)</time_frame>
    <description>Will include body serum albumin and summarized using mean +/- standard error of mean, range, and median at each time point. Graphical analyses will be largely used to assess potential patterns and relationships.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in levels of circulating cytotoxic T cells</measure>
    <time_frame>Day 1 of Cycle 1,3,5,7 (each cycle is 14 days)</time_frame>
    <description>Will be assessed using peripheral blood mononuclear cells and summarized using mean +/- standard error of mean, range, and median at each time point. Graphical analyses will be largely used to assess potential patterns and relationships.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Metastatic Colorectal Carcinoma</condition>
  <condition>Stage IV Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVA Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVB Colorectal Cancer AJCC v8</condition>
  <condition>Stage IVC Colorectal Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (riluzole, mFOLFOX6, bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive riluzole PO BID on days 1-14. Patients also receive oxaliplatin via IVPB over 2 hours, leucovorin calcium IVPB over 2 hours, and bevacizumab IVPB over 30 minutes on day 1 and fluorouracil via IV push over 5 minutes and then IV continuously over 46 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IVPB</description>
    <arm_group_label>Treatment (riluzole, mFOLFOX6, bevacizumab)</arm_group_label>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab awwb</other_name>
    <other_name>Bevacizumab Biosimilar BEVZ92</other_name>
    <other_name>Bevacizumab Biosimilar BI 695502</other_name>
    <other_name>Bevacizumab Biosimilar CBT 124</other_name>
    <other_name>Bevacizumab Biosimilar CT-P16</other_name>
    <other_name>Bevacizumab Biosimilar FKB238</other_name>
    <other_name>Bevacizumab Biosimilar GB-222</other_name>
    <other_name>Bevacizumab Biosimilar HD204</other_name>
    <other_name>Bevacizumab Biosimilar HLX04</other_name>
    <other_name>Bevacizumab Biosimilar IBI305</other_name>
    <other_name>Bevacizumab Biosimilar LY01008</other_name>
    <other_name>Bevacizumab Biosimilar MIL60</other_name>
    <other_name>Bevacizumab Biosimilar Mvasi</other_name>
    <other_name>Bevacizumab Biosimilar QL 1101</other_name>
    <other_name>Bevacizumab Biosimilar RPH-001</other_name>
    <other_name>Bevacizumab Biosimilar SCT501</other_name>
    <other_name>Bevacizumab Biosimilar Zirabev</other_name>
    <other_name>Bevacizumab-awwb</other_name>
    <other_name>Bevacizumab-bvzr</other_name>
    <other_name>BP102</other_name>
    <other_name>BP102 Biosimilar</other_name>
    <other_name>HD204</other_name>
    <other_name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</other_name>
    <other_name>Mvasi</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
    <other_name>SCT501</other_name>
    <other_name>Zirabev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (riluzole, mFOLFOX6, bevacizumab)</arm_group_label>
    <other_name>5 Fluorouracil</other_name>
    <other_name>5 Fluorouracilum</other_name>
    <other_name>5 FU</other_name>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-Fu</other_name>
    <other_name>5FU</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Carac</other_name>
    <other_name>Fluoro Uracil</other_name>
    <other_name>Fluouracil</other_name>
    <other_name>Flurablastin</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluril</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
    <other_name>Ro-2-9757</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Given IVPB</description>
    <arm_group_label>Treatment (riluzole, mFOLFOX6, bevacizumab)</arm_group_label>
    <other_name>Adinepar</other_name>
    <other_name>Calcifolin</other_name>
    <other_name>Calcium (6S)-Folinate</other_name>
    <other_name>Calcium Folinate</other_name>
    <other_name>Calcium Leucovorin</other_name>
    <other_name>Calfolex</other_name>
    <other_name>Calinat</other_name>
    <other_name>Cehafolin</other_name>
    <other_name>Citofolin</other_name>
    <other_name>Citrec</other_name>
    <other_name>Citrovorum Factor</other_name>
    <other_name>Cromatonbic Folinico</other_name>
    <other_name>Dalisol</other_name>
    <other_name>Disintox</other_name>
    <other_name>Divical</other_name>
    <other_name>Ecofol</other_name>
    <other_name>Emovis</other_name>
    <other_name>Factor, Citrovorum</other_name>
    <other_name>Flynoken A</other_name>
    <other_name>Folaren</other_name>
    <other_name>Folaxin</other_name>
    <other_name>FOLI-cell</other_name>
    <other_name>Foliben</other_name>
    <other_name>Folidan</other_name>
    <other_name>Folidar</other_name>
    <other_name>Folinac</other_name>
    <other_name>Folinate Calcium</other_name>
    <other_name>folinic acid</other_name>
    <other_name>Folinic Acid Calcium Salt Pentahydrate</other_name>
    <other_name>Folinoral</other_name>
    <other_name>Folinvit</other_name>
    <other_name>Foliplus</other_name>
    <other_name>Folix</other_name>
    <other_name>Imo</other_name>
    <other_name>Lederfolat</other_name>
    <other_name>Lederfolin</other_name>
    <other_name>Leucosar</other_name>
    <other_name>leucovorin</other_name>
    <other_name>Rescufolin</other_name>
    <other_name>Rescuvolin</other_name>
    <other_name>Tonofolin</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Given IVPB</description>
    <arm_group_label>Treatment (riluzole, mFOLFOX6, bevacizumab)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Ai Heng</other_name>
    <other_name>Aiheng</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Diaminocyclohexane Oxalatoplatinum</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Eloxatine</other_name>
    <other_name>JM-83</other_name>
    <other_name>Oxalatoplatin</other_name>
    <other_name>Oxalatoplatinum</other_name>
    <other_name>RP 54780</other_name>
    <other_name>RP-54780</other_name>
    <other_name>SR-96669</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (riluzole, mFOLFOX6, bevacizumab)</arm_group_label>
    <other_name>Rilutek</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with metastatic colorectal cancer, who are appropriate candidates to receive&#xD;
             mFOLFOX6/bevacizumab. Patients who progressed on FOLFOX-based regimen are allowed&#xD;
&#xD;
          -  Willingness to undergo both pre-treatment and post-treatment tumor tissue biopsies&#xD;
             (pre-treatment tumor tissue will be sent to pathology lab to confirm metastatic&#xD;
             colorectal cancer as the standard of care)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= (ANC) 1,500/ul&#xD;
&#xD;
          -  Platelets &gt;= 100,000/ul&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dl&#xD;
&#xD;
          -  Serum total bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
          -  Serum albumin &gt;= 2.5 g/dl&#xD;
&#xD;
          -  If no liver involvement, aspartate aminotransferase (AST) and alanine aminotransferase&#xD;
             (ALT) =&lt; 1.5 x ULN. If liver involvement, AST and ALT =&lt; 3.0 x ULN&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  A male subject of fathering potential must use an adequate method of contraception to&#xD;
             avoid conception throughout the study (and for up to 12 weeks after the last dose of&#xD;
             study drug) to minimize the risk of pregnancy. If the partner is pregnant or&#xD;
             breastfeeding, the subject must use a condom&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must be using an adequate method of&#xD;
             contraception to avoid pregnancy throughout the study and for up to 12 weeks after the&#xD;
             last dose of study drug to minimize the risk of pregnancy. WOCBP must have a negative&#xD;
             serum or urine pregnancy test within 72 hours before the start of the investigational&#xD;
             product&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents&#xD;
&#xD;
          -  Patients with history of hepatitis B or C&#xD;
&#xD;
          -  Patients with severe renal impairment (CrCl &lt; 30 mL/min)&#xD;
&#xD;
          -  Prior full field radiotherapy &lt; 4 weeks or limited field radiotherapy &lt; 2 weeks prior&#xD;
             to first study drug administration. Patients with central nervous system (CNS)&#xD;
             metastases may participate in this trial provided they are clinically stable. Patients&#xD;
             who are &lt; 1 month from radiation therapy must not be included&#xD;
&#xD;
          -  Patients with existing grade 2 peripheral neuropathy&#xD;
&#xD;
          -  Patients with a history of thrombotic or embolic events within the last six months&#xD;
             such as a cerebrovascular accident (including transient ischemic attacks), pulmonary&#xD;
             embolism or deep vein thrombosis&#xD;
&#xD;
          -  Cardiac conditions as follows:&#xD;
&#xD;
               -  Active coronary artery disease, unstable or newly diagnosed angina or myocardial&#xD;
                  infarction less than 6 months prior to first study drug administration&#xD;
&#xD;
               -  Class III-IV New York Heart Association (NYHA) congestive heart failure&#xD;
&#xD;
               -  Uncontrolled hypertension (Systolic blood pressure [BP] &gt; 150 mmHg and diastolic&#xD;
                  BP &gt; 90 mmHg for 24 hours) despite optimal medical management&#xD;
&#xD;
               -  Corrected QT (QTc) (Friderica) prolongation &gt; 480 msec&#xD;
&#xD;
          -  Uncontrolled concurrent illness including, but not limited to, ongoing or active&#xD;
             infection, cardiac arrhythmia, active bleeding diatheses, and psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Major surgical procedure or significant traumatic injury less than 3 weeks or those&#xD;
             who receive minor surgical procedures within 1 week from first dose of study drug&#xD;
             administration&#xD;
&#xD;
          -  Known inability to swallow capsules&#xD;
&#xD;
          -  Inability to comply with study and/or follow-up procedures&#xD;
&#xD;
          -  Pregnant women are excluded from this study. Because there is an unknown but potential&#xD;
             risk for adverse events in nursing infants secondary to treatment of the mother,&#xD;
             breastfeeding should be discontinued&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ning Jin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>The Ohio State University Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ning Jin, MD</last_name>
      <phone>614-366-8525</phone>
      <email>ning.jin2@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Ning Jin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Ning Jin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Riluzole</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

